Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 202
Go back to Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 202| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 59.38 +0.17 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.21 | 52 Week High | $19.98 | |||
| Open | $58.88 | 52 Week Low | $10.52 | |||
| Day High | $60.75 | P/E | N/A | |||
| Day Low | $58.88 | EPS | $-1.45 | |||
| Volume | 534,203 | |||||
